Pear Therapeutics, Inc. (PEAR): Price and Financial Metrics


Pear Therapeutics, Inc. (PEAR): $0.34

0.13 (+59.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PEAR POWR Grades

  • Sentiment is the dimension where PEAR ranks best; there it ranks ahead of 88.24% of US stocks.
  • The strongest trend for PEAR is in Growth, which has been heading up over the past 178 days.
  • PEAR's current lowest rank is in the Growth metric (where it is better than 5.87% of US stocks).

PEAR Stock Summary

  • With a one year PEG ratio of 0.45, PEAR THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.03% of US stocks.
  • As for revenue growth, note that PEAR's revenue has grown 172.08% over the past 12 months; that beats the revenue growth of 95.67% of US companies in our set.
  • PEAR THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -265.61%, greater than the shareholder yield of only 2.46% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to PEAR THERAPEUTICS INC, a group of peers worth examining would be VIAV, IBIO, VNDA, EGAN, and ALKS.
  • To dig deeper into the stock's financial statements, go to PEAR's page on browse-edgar?action=getcompany&CIK=0001835567.

PEAR Valuation Summary

  • In comparison to the median Technology stock, PEAR's EV/EBIT ratio is 112.7% lower, now standing at -2.4.
  • Over the past 26 months, PEAR's price/sales ratio has gone down 20.

Below are key valuation metrics over time for PEAR.

Stock Date P/S P/B P/E EV/EBIT
PEAR 2023-03-14 7.6 1.7 -2.9 -2.4
PEAR 2023-03-13 6.9 1.5 -2.6 -2.1
PEAR 2023-03-10 7.4 1.6 -2.8 -2.3
PEAR 2023-03-09 8.8 1.9 -3.3 -2.9
PEAR 2023-03-08 10.0 2.2 -3.8 -3.4
PEAR 2023-03-07 11.3 2.5 -4.3 -3.9

PEAR Stock Price Chart Interactive Chart >

Price chart for PEAR

PEAR Price/Volume Stats

Current price $0.34 52-week high $6.74
Prev. close $0.21 52-week low $0.20
Day low $0.25 Volume 20,415,883
Day high $0.48 Avg. volume 602,758
50-day MA $0.99 Dividend yield N/A
200-day MA $1.69 Market Cap 46.92M

Pear Therapeutics, Inc. (PEAR) Company Bio


Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.


PEAR Latest News Stream


Event/Time News Detail
Loading, please wait...

PEAR Latest Social Stream


Loading social stream, please wait...

View Full PEAR Social Stream

Latest PEAR News From Around the Web

Below are the latest news stories about PEAR THERAPEUTICS INC that investors may wish to consider to help them evaluate PEAR as an investment opportunity.

Pear Therapeutics Announces Process Exploring Strategic Alternatives

BOSTON, March 17, 2023--Pear Therapeutics Announces Process Exploring Strategic Alternatives

Yahoo | March 17, 2023

Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

BOSTON, February 27, 2023--Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

Yahoo | February 27, 2023

Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BOSTON, February 02, 2023--Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Yahoo | February 2, 2023

Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

BOSTON, January 26, 2023--Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

Yahoo | January 26, 2023

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

BOSTON, January 18, 2023--Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Yahoo | January 18, 2023

Read More 'PEAR' Stories Here

PEAR Price Returns

1-mo -68.22%
3-mo -75.36%
6-mo -79.14%
1-year -92.83%
3-year N/A
5-year N/A
YTD -71.19%
2022 -80.97%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9287 seconds.